Heartland Osteoporosis Prevention Study

PHASE3CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

February 1, 2015

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2019

Conditions
Osteopenia
Interventions
DRUG

Calcium Carbonate

Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)

DRUG

Vitamin D3

Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.

DRUG

Risedronate

Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.

BEHAVIORAL

Bone-loading exercises

Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

Creighton University Medical Center

OTHER

lead

University of Nebraska

OTHER

NCT02186600 - Heartland Osteoporosis Prevention Study | Biotech Hunter | Biotech Hunter